<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.peertechzpublications.org/assets/xsl/oaitohtml.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
										<responseDate>2026-05-09T22:32:17Z</responseDate>
										<request verb="GetRecord" metadataPrefix="oai_dc" identifier="oai:www.peertechzpublications.org:10.17352/jgro.000088">https://www.peertechzpublications.org/oai-pmh</request><GetRecord><record>
								<header>
									<identifier>oai:www.peertechzpublications.org:10.17352/jgro.000088</identifier>
									<datestamp>2020-09-14</datestamp>
									<setSpec>PTZ.JGRO:VOL6</setSpec>
								</header>
								<metadata>
									<oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
										<dc:title>
										Clinical significance of sex hormones in COVID-19
										</dc:title><dc:creator>Nasser Mikhail</dc:creator><dc:creator>Soma Wali</dc:creator><dc:description>&lt;p&gt;Background: Sex hormones may play a role in excess male lethality from coronavirus disease-2019 (COVID-19).&lt;/p&gt;&lt;p&gt;Objective: To clarify the implications of testosterone and estradiol in the course and prognosis of COVID-19 in men and women.&lt;/p&gt;&lt;p&gt;Methods: PUBMED search until September 7, 2020. Search terms included: COVID-19, sex hormones, testosterone, estrogen, androgen-deprivation, mortality. Due to lack of randomized trials, we included retrospective trials, case series, and pre-print studies.&lt;/p&gt;&lt;p&gt;Results: In men hospitalized with COVID-19, circulating testosterone levels are generally decreased and inversely correlated with pro-inflammatory cytokines. Low testosterone levels may be associated with severe COVID-19 and high mortality. Yet, androgen deprivation therapy as treatment of prostate cancer may be associated with decreased hospitalization and favorable clinical outcomes in COVID-19. In women hospitalized with COVID-19, high testosterone levels directly correlate with pro-inflammatory cytokines. In premenopausal women, estradiol serum levels above 70 pg/ml were associated with decreased risk of having severe COVID-19. Pre-menopausal women using combined oral contraceptives may have decreased risk of COVID-19. Conversely, post-menopausal women taking hormone replacement therapy may have increased risk. In general, pregnant women with COVID-19 seem to have similar disease course as non-pregnant women, but studies were lacking adequate control subjects.&amp;nbsp;&lt;/p&gt;&lt;p&gt;Conclusions: Preliminary data suggest that androgen deprivation therapy and estrogen could be beneficial as potential treatment of COVID-19 in men and women, respectively. However, the possible therapeutic role of these agents will be only confirmed by randomized trials.&amp;nbsp;&lt;/p&gt;</dc:description>
										<dc:publisher>Journal of Gynecological Research and Obstetrics - Peertechz Publications</dc:publisher>
										<dc:date>2020-09-14</dc:date>
										<dc:type>Review Article</dc:type>
										<dc:identifier>https://doi.org/10.17352/jgro.000088</dc:identifier>
										<dc:language>en</dc:language>
										<dc:rights>Copyright © Nasser Mikhail et al.</dc:rights>
									</oai_dc:dc>
								</metadata>
							</record></GetRecord>
						</OAI-PMH>
